


What is claimed is:

1. A compound of formula (I):



where:

$\text{A}^1$  and  $\text{A}^2$  are the same or different aryl groups collectively bearing at least one hydrophilic substituent;

$\text{E}^1$  and  $\text{E}^2$  are the same or different and are O, S, or  $\text{NR}^2$  (where  $\text{R}^2$  is a linear or branched  $\text{C}_1$ - $\text{C}_{20}$  carbon containing group);

M is H or a pharmaceutically acceptable monovalent cation;

$\text{R}^1$  is a linear or branched, saturated or unsaturated,  $\text{C}_1$ - $\text{C}_{20}$  carbon containing group;

Z is a single bond, a carbonyl,  $\text{CE}^3\text{E}^4$ , or  $\text{CR}^3\text{E}^3$ , where

$\text{E}^3$  and  $\text{E}^4$  are the same or different and are  $\text{OR}^4$ ,  $\text{SR}^4$ , or  $\text{NR}^4_2$ , where


$\text{R}^3$  is a linear or branched  $\text{C}_1$ - $\text{C}_{20}$  carbon containing group, and

$\text{R}^4$  is H or a linear or branched  $\text{C}_1$ - $\text{C}_{20}$  carbon containing group; and

n is 0 or 1, or a pharmaceutically acceptable salt thereof,

provided that the compound is not 4'-phosphophloretin or a pharmaceutically acceptable salt thereof.


2. The compound of Claim 1 that is a compound of formula (Ia):



where:

$\text{A}^1$ ,  $\text{A}^2$ ,  $\text{E}^1$ ,  $\text{M}$ ,  $\text{R}^1$  and  $\text{Z}$  are as defined in Claim 1, or a pharmaceutically acceptable salt thereof, provided that the compound is not 4'-phosphophloretin or a pharmaceutically acceptable salt thereof.


3. The compound of Claim 1 that is a compound of formula (Ib):



where:

$\text{A}^1$ ,  $\text{A}^2$ ,  $\text{M}$ ,  $\text{R}^1$  and  $\text{Z}$  are as defined in Claim 1, or a pharmaceutically acceptable salt thereof, provided that the compound is not 4'-phosphophloretin or a pharmaceutically acceptable salt thereof.


4. The compound of Claim 1 that is a compound of formula (Ic):



where:

A<sup>1</sup>, A<sup>2</sup>, M, R<sup>1</sup> and Z are as defined in Claim 1, or a pharmaceutically acceptable salt thereof.


5. The compound of claim 1 that is a compound of formula (Id):



where:

A<sup>1</sup>, A<sup>2</sup>, M, R<sup>1</sup> and Z are as defined in Claim 1, or a pharmaceutically acceptable salt thereof.


6. The compound of claim 1 that is a compound of formula (Ie):



where:

A<sup>1</sup>, A<sup>2</sup>, M, and R<sup>1</sup> are as defined in Claim 1, or a pharmaceutically acceptable salt thereof, provided that the compound is not 4'-phosphophloretin or a pharmaceutically acceptable salt thereof.


7. The compound of claim 1 that is a compound of formula (If):



where:

A<sup>1</sup>, A<sup>2</sup>, M, and R<sup>1</sup> are as defined in Claim 1, or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1 that is a compound of formula (Ig):




where:

A<sup>1</sup>, A<sup>2</sup>, M, and R<sup>1</sup> are as defined in Claim 1, or a pharmaceutically acceptable salt thereof.

9. The compound of Claim 1 that is 2'-phosphophloretin, 2'-thiophosphophloretin or 2'-aminophosphophloretin or a pharmaceutically acceptable salt thereof.

10. A medication comprising a carrier and a therapeutically effective amount of a compound of formula (I):



where:

$A^1$  and  $A^2$  are the same or different aryl groups collectively bearing at least one hydrophilic substituent;

$E^1$  and  $E^2$  are the same or different and are O, S, or  $NR^2$  (where  $R^2$  is a linear or branched  $C_1$ - $C_{20}$  carbon containing group);

M is H or a pharmaceutically acceptable monovalent cation;

$R^1$  is a linear or branched, saturated or unsaturated,  $C_1$ - $C_{20}$  carbon containing group;

Z is a single bond, a carbonyl,  $CE^3E^4$ , or  $CR^3E^3$ , where

$E^3$  and  $E^4$  are the same or different and are  $OR^4$ ,  $SR^4$ , or  $NR^4_2$ , where


$R^3$  is a linear or branched  $C_1$ - $C_{20}$  carbon containing group, and

$R^4$  is H or a linear or branched  $C_1$ - $C_{20}$  carbon containing group; and

n is 0 or 1,

or a pharmaceutically acceptable salt thereof.


11. The medication of Claim 10 where the compound is a compound of formula (Ia):



where:

$A^1$ ,  $A^2$ ,  $E^1$ , M,  $R^1$  and Z are as defined in Claim 10, or a pharmaceutically acceptable salt thereof.


12. The medication of Claim 10 where the compound is a compound of formula (Ib):



where:

$\text{A}^1$ ,  $\text{A}^2$ ,  $\text{M}$ ,  $\text{R}^1$  and  $\text{Z}$  are as defined in Claim 10, or a pharmaceutically acceptable salt thereof.


13. The medication of Claim 10 where the compound is a compound of formula (Ic):



where:

$\text{A}^1$ ,  $\text{A}^2$ ,  $\text{M}$ ,  $\text{R}^1$  and  $\text{Z}$  are as defined in Claim 10, or a pharmaceutically acceptable salt thereof.


14. The medication of Claim 10 where the compound is a compound of formula (Id):



where:

$\text{A}^1$ ,  $\text{A}^2$ ,  $\text{M}$ ,  $\text{R}^1$  and  $\text{Z}$  are as defined in Claim 10, or a pharmaceutically acceptable salt thereof.


15. The medication of Claim 10 where the compound is a compound of formula (Ie):



where:

$\text{A}^1$ ,  $\text{A}^2$ ,  $\text{M}$ , and  $\text{R}^1$  are as defined in Claim 10, or a pharmaceutically acceptable salt thereof.


16. The medication of Claim 10 where the compound is a compound of formula (If):



where:

$\text{A}^1$ ,  $\text{A}^2$ ,  $\text{M}$ , and  $\text{R}^1$  are as defined in Claim 10, or a pharmaceutically acceptable salt thereof.

17. The medication of Claim 10 where the compound is a compound of formula (Ig):




where:

$\text{A}^1$ ,  $\text{A}^2$ ,  $\text{M}$ , and  $\text{R}^1$  are as defined in Claim 10, or a pharmaceutically acceptable salt thereof.

202070708-010702

18. The medication of Claim 10 where the compound is 2'-phosphophloretin, 2'-thiophosphophloretin or 2'-aminophosphophloretin or a pharmaceutically acceptable salt thereof.

19. A method of inhibiting sodium-mediated phosphate uptake, reducing serum PTH, calcium, calcitriol, or phosphate, or treating renal disease, comprising administration of a compound of formula (I):



where:

A<sup>1</sup> and A<sup>2</sup> are the same or different aryl groups collectively bearing at least one hydrophilic substituent;

E<sup>1</sup> and E<sup>2</sup> are the same or different and are O, S, or NR<sup>2</sup> (where R<sup>2</sup> is a linear or branched C<sub>1</sub>-C<sub>20</sub> carbon containing group);

M is H or a pharmaceutically acceptable monovalent cation;

R<sup>1</sup> is a linear or branched, saturated or unsaturated, C<sub>1</sub>-C<sub>20</sub> carbon containing group;

Z is a single bond, a carbonyl, CE<sup>3</sup>E<sup>4</sup>, or CR<sup>3</sup>E<sup>3</sup>, where

E<sup>3</sup> and E<sup>4</sup> are the same or different and are OR<sup>4</sup>, SR<sup>4</sup>, or NR<sup>4</sup>, where

R<sup>3</sup> is a linear or branched C<sub>1</sub>-C<sub>20</sub> carbon containing group, and


R<sup>4</sup> is H or a linear or branched C<sub>1</sub>-C<sub>20</sub> carbon containing group; and

n is 0 or 1, or a pharmaceutically acceptable salt thereof.

20. The method of Claim 19 where the compound is a compound of formula (Ia):



60



where:

A<sup>1</sup>, A<sup>2</sup>, E<sup>1</sup>, M, R<sup>1</sup> and Z are as defined in Claim 19, or a pharmaceutically acceptable salt thereof.

2020-01-03 10:00:00

*[Handwritten signature]*